Recent progress in antibody-based therapeutics for triple-negative breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Recent progress in antibody-based therapeutics for triple-negative breast cancer

Published:2022-07-03 Issue:7 Volume:19 Page:815-832
ISSN:1742-5247
Container-title:Expert Opinion on Drug Delivery
language:en
Short-container-title:Expert Opinion on Drug Delivery

Author:

Ning Wen-Jing¹,Liu Xue¹,Zeng Hong-Ye¹,an Zhi-Qiang²,Luo Wen-Xin¹^ORCID,Xia Ning-Shao¹^ORCID

Affiliation:

1. State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics & National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Public Health, Xiamen University, Xiamen, Fujian, China

2. Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX, USA

Funder

National Natural Science Foundation of China

China Postdoctoral Science Foundation

Publisher

Informa UK Limited

Subject

Pharmaceutical Science

Link

https://www.tandfonline.com/doi/pdf/10.1080/17425247.2022.2093853

Reference155 articles.

1. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

2. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment

3. Triple negative breast cancer: Deciphering the biology and heterogeneity

4. Adjuvant and Neoadjuvant Treatment of Triple-Negative Breast Cancer With Chemotherapy

5. Auranofin/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Triple-Negative Breast Cancer Treatment Advancements: A Review of Evolving Strategies;European Journal of Cancer Care;2024-04-08

2. Exploring the oncogenic and tumor-suppressive roles of Circ-ADAM9 in cancer;Pathology - Research and Practice;2024-04

3. EVOLUTION AND APPLICATIONS OF RADIOPHARMACEUTICALS IN NUCLEAR DENTISTRY: A COMPREHENSIVE OVERVIEW;ROM J ORAL REHABIL;2024

4. Breast cancer organoids and their applications for precision cancer immunotherapy;World Journal of Surgical Oncology;2023-10-26

5. Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens;Frontiers in Oncology;2023-07-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3